D-0327-2024 Class II Terminated

Recalled by Amneal Pharmaceuticals Of New York, LLC — Brookhaven, NY

FDA drug recall D-0327-2024 was initiated by Amneal Pharmaceuticals Of New York, LLC on Feb 13, 2024 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: Out-of-specification test results. The recall status is terminated (terminated Feb 14, 2025). Affected quantity: 46,037 Bottles.

Recall details

Product Type
Drugs
Report Date
Feb 28, 2024
Initiation Date
Feb 13, 2024
Termination Date
Feb 14, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
46,037 Bottles

Product description

Oseltamivir Phosphate for Oral Suspension 6mg/ml, 60 mL (reconstituted) bottle, RX only, Distributed by Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807. NDC# 69238-1273-6

Reason for recall

Failed Impurities/Degradation Specifications: Out-of-specification test results.

Distribution pattern

Nationwide in the USA

Code information

Lot # BF22722A, Exp. 08/31/2024; BJ15122A, Exp. 09/30/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0327-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0327-2024. Report a data issue: hello@regdatalab.com.